Influenza Vaccination of Swine Reduces Public Health Risk at the Swine-Human Interface

Joshua N. Lorbach,a Sarah W. Nelson,a Sarah E. Lauterbach,a Jacqueline M. Nolting,a Eben Kenah,a Dillon S. McBride,a Marie R. Culhane,b Christa Goodell,c Andrew S. Bowmana

aThe Ohio State University, Columbus, Ohio, USA
bUniversity of Minnesota, St. Paul, Minnesota, USA
cBoehringer Ingelheim Vetmedica, Inc., Duluth, Georgia, USA

ABSTRACT Influenza A viruses (IAV) in swine (IAV-S) pose serious risk to public health through spillover at the human-animal interface. Continued zoonotic transmission increases the likelihood novel IAV-S capable of causing the next influenza pandemic will emerge from this animal reservoir. Because current mitigation strategies are insufficient to prevent IAV zoonosis, we investigated the ability of swine vaccination to decrease IAV-S zoonotic transmission risk. We assessed postchallenge viral shedding in market-age swine vaccinated with either live-attenuated influenza virus (LAIV), killed influenza virus (KV), or sham vaccine (NV). We also assessed postchallenge transmission by exposing naive ferrets to pigs with contact types reflective of those experienced by humans in a field setting. LAIV and KV swine groups exhibited a nearly 100-fold reduction in peak nasal titer (LAIV mean, 4.55 log 50% tissue culture infectious dose [TCID50]/ml; KV mean, 4.53 log TCID50/ml) compared to NV swine (mean, 6.40 log TCID50/ml). Air sampling during the postchallenge period revealed decreased cumulative IAV in LAIV and KV study room air (LAIV, area under the concentration-time curve [AUC] of 57.55; KV, AUC = 24.29) compared to the NV study room (AUC = 86.92). Pairwise survival analysis revealed a significant delay in onset of infection among ferrets exposed to LAIV pigs versus NV pigs (rate ratio, 0.66; P = 0.028). Ferrets exposed to vaccinated pigs had lower cumulative virus titers in nasal wash samples (LAIV versus NV, P < 0.0001; KV versus NV, P = 0.3490) and experienced reduced clinical signs during infection. Our findings support the implementation of preexhibition influenza vaccination of swine to reduce the public health risk posed by IAV-S at agricultural exhibitions.

IMPORTANCE Swine exhibited at agricultural fairs in North America have been the source of repeated zoonotic influenza A virus transmission, which creates a pathway for influenza pandemic emergence. We investigated the effect of using either live-attenuated influenza virus or killed influenza virus vaccines as prefair influenza vaccination of swine on zoonotic transmission risk. Ferrets were exposed to the pigs in order to simulate human exposure in a field setting. We observed reductions in influenza A virus shedding in both groups of vaccinated pigs as well as the corresponding ferret exposure groups, indicating vaccination improved outcomes on both sides of the interface. There was also significant delay in onset of infection among ferrets that were exposed to live-attenuated virus-vaccinated pigs, which might be beneficial during longer fairs. Our findings indicate that policies mandating influenza vaccination of swine before fairs, while not currently common, would reduce the public health risk posed by influenza zoonosis.

KEYWORDS disease transmission, infectious, infectious disease, influenza A virus, preventive medicine, swine, transmission, vaccines, zoonoses
nterspecies transmission of influenza A viruses (IAV) represents a crucial pathway for emergence of novel IAVs that can significantly affect public health in the form of influenza outbreaks, epidemics, and pandemics. Prolonged contact between swine and humans at agricultural exhibitions in the United States and Mexico has been associated with hundreds of cases of human infection with swine-origin IAV (IAV-S), which makes fairs an important swine-human interface in terms of zoonotic transmission (1, 2). Bidirectional spillover events at this interface can have immediate and long-term effects on both human and animal health.

Given the repeated zoonotic IAV transmission that has occurred at agricultural exhibitions, or fairs, evidence-based mitigation strategies are needed to prevent IAV transmission between swine and humans. Agricultural fairs are unique swine concentration points because pigs with varied IAV exposure histories travel from distant localities to participate, allowing a few infected pigs to potentially infect a large number of immunologically naive pigs (3). Increased IAV prevalence in pigs at a fair increases the likelihood that susceptible humans coming into contact with swine at fairs will become infected with zoonotic influenza (4). Therefore, many strategies designed to mitigate the risk posed by IAV-S at the human-animal interface are focused on reducing the prevalence of IAV in swine (5).

Influenza is frequently subclinical in swine, making it nearly impossible to prevent entry of IAV-infected pigs into exhibitions (6). Animal and public health officials recommend shortening swine exhibitions to limit IAV amplification in swine and reduce the opportunity for spillover to humans (5, 7). The Centers for Disease Control and Prevention recommend individuals involved with swine shows receive annual seasonal influenza vaccinations, although this is primarily aimed toward prevention of transmission of seasonal IAVs from people to swine (8). Additional approaches to minimizing risk posed by IAV-S include educating the public who attend swine shows with signage that indicates young children, pregnant women, elderly individuals, and those with immunologic or cardiovascular health conditions may be at increased risk of infection or severe complications associated with influenza (9). Other prevention strategies include promoting personal hygiene by placing handwashing stations in the vicinity and separating food service areas from swine barns (5).

Pre-exhibition influenza vaccination of pigs has been considered a method to reduce the prevalence of IAV in exhibition swine. Exhibitors are advised to consult a veterinarian about administering influenza vaccines, but vaccination of pigs is not required at all exhibitions (5). Multiple IAV vaccine products are licensed for use in swine, but no studies have assessed the ability of these products to protect public health at the swine-human interface (10, 11). We sought to validate the implementation of swine influenza vaccination as a mitigation strategy to reduce the risk of spillover of IAV-S from swine to humans. We hypothesized that vaccination of swine could reduce the public health threat posed by IAV-S. To assess this, we compared the effect swine vaccination had on postchallenge viral shedding and subsequent transmission to naive ferrets in near exposure (NE) or far exposure (FE) using a translational study designed to simulate contact between IAV-infected swine and humans at agricultural exhibitions.

RESULTS

Swine virus infection and shedding. All study swine were IAV positive by PCR 1 day postchallenge (dpc). Peak nasal swab titers were nearly 100-fold lower in live-attenuated influenza virus (LAIV)-vaccinated pigs than in sham-vaccinated (NV) pigs. Cumulative nasal virus shedding among swine in the LAIV and killed influenza virus (KV) groups were significantly reduced compared to the NV group, and comparison of LAIV and KV pigs revealed similar cumulative nasal shedding (see Table S1 in the supplemental material). Viral shedding peaked at 5 dpc in NV swine, whereas peak shedding occurred at 3 dpc for LAIV and KV swine (Fig. 1 and Table S2). Infectious IAV shedding ceased by 7 dpc for LAIV and KV pigs and by 9 dpc for NV pigs. No LAIV pigs were shedding infectious virus at 9 dpc; however, a single LAIV pig was isolation positive at 11 dpc.
Three NV pigs experienced increases in respiratory rate above 40 breaths per minute following challenge. No clinical signs indicating respiratory distress were appreciated in LAIV or KV pigs. Lethargy was noted in all NV pigs following challenge, with one or more lethargic pigs observed between 4 and 10 dpc. In comparison, lethargy was observed in all KV pigs at 4 dpc and in one LAIV pig at 2 dpc.

Swine-to-ferret transmission. The cumulative IAV genome copy number per liter of air was lower for the LAIV and KV groups than the NV group. IAV air levels for the NV group rose sharply before peaking at 5 dpc, corresponding with peak nasal shedding in NV swine (Fig. 1 and 2). Peak IAV air levels for the KV swine also occurred at 5 dpc, whereas peak levels for the LAIV swine occurred at 9 dpc.

All ferrets in the KV and NV groups were IAV positive by PCR at 2 days postexposure (dpe); infectious virus was recovered from five of six ferrets in the NV group and all three of the NE ferrets in the KV group. In contrast, while five of six ferrets in the LAIV group were PCR positive at 2 dpe, we did not recover any infectious IAV (Fig. 3 and Fig. S1). Infectious IAV recovery was delayed until 4 dpe for NE and FE ferrets in the LAIV group and for FE ferrets in the KV group. Overall, mean nasal shedding in all ferret groups peaked at 4 dpe (Fig. 3 and Fig. S1, Table S2). When further examined by

*FIG 1* Mean (n=5) swine nasal swab influenza A virus (IAV) titers are shown by vaccination group: live-attenuated influenza virus (LAIV), killed influenza virus (KV), or sham vaccine (NV). N = 5 pigs per group. Spikes indicate standard errors of the means (SEM). The lower x axis indicates individual study days, and values are skewed (±0.1) to allow comparison of overlapping error bars. The upper x axis denotes timeline points of interest. Fomite transfer occurred between pigs and near-exposed (NE) ferrets only. The corresponding table below line plot indicates number of animals shedding infectious virus, defined as an individual titer in excess of the assay limit of detection (LOD; 1.5 log TCID₅₀/ml) by study day. Titers at or below LOD were assigned a nominal value of 0.0 for mean calculations.
exposure type, peak nasal shedding for FE ferrets in the LAIV group was delayed until 8 dpe (Fig. S1). There was one NE ferret in the LAIV group whose nasal wash viral titers were consistently below the assay LOD despite PCR-confirmed exposure to virus.

Onset of clinical signs, including nasal discharge, lethargy, and elevated temperatures, was delayed, and severity was reduced in ferrets in the LAIV group compared to ferrets in the NV group (Fig. 4 and 5 and Fig. S2). Onset of nasal signs and lethargy were similar between ferrets in the KV and NV groups, although lethargy was more severe in the NV group (see Fig. 6). Mean weight loss was mild in all three ferret groups (Fig. 5). Weight loss in NV group ferrets began soon after exposure but was delayed by several days in LAIV (NE and FE) and KV (NE) ferret groups (Fig. S3). Mean daily rectal temperatures within the LAIV ferret group gradually increased following exposure, whereas temperatures in the KV and NV groups initially decreased below baseline at 2 dpe and subsequently increased above baseline at 4 dpe (Fig. S2).

IAV sequences recovered from nasal washes from all ferrets were >99% identical to the inoculation strain. Upon examination of the hemagglutinin (HA) sequences, a change from alanine to serine at amino acid residue 138 (A138S, H3 numbering) was observed in IAV sequences from one of six LAIV group ferrets, six of six KV group ferrets, and three of six NV group ferrets. Sequencing did not identify any additional known functional mutations.

Pairwise survival analysis. The estimated RR obtained from pairwise survival analysis of swine-to-ferret transmission for ferrets exposed to LAIV pigs indicated a significant delay in infection compared with ferrets exposed to NV pigs (RR = 0.66, P = 0.028) (Table 1). The estimated odds ratio (OR) for LAIV ferret group compared to NV ferret group was 0.19 (95% confidence interval [CI], 0.04, 0.84), corresponding to an estimated vaccine efficacy (VE) of 81% (95% CI, 16%, 96%) (Table 2). The estimated shape parameter was 4.06 (2.77, 5.60), so the RRs and ORs are quite different (Tables 1 and 2). Point estimates suggest that the KV also delayed the onset of infection in ferrets and
that FE ferrets had longer times to infection than NE ferrets (Tables 1 and 2). However, these results were not statistically significant, likely due to small sample size.

**End-of-study respiratory tract pathology and virus detection.** Microscopic lesions in swine respiratory tissues demonstrated variable chronicity based on inflammatory cell populations and mucosal response to previous damage. Aggregate lung pathology scores were elevated in the KV swine group compared to NV swine ($P = 0.0088$). No significant differences in nasal pathology scores were apparent between groups.

Microscopic lesions in ferret respiratory tissues were relatively acute and primarily consisted of necrotizing bronchiolitis. No significant differences in nasal pathology scores and aggregate lung pathology scores were found between ferret groups.

IAV was not detected in homogenized lung tissue from any pigs in the LAIV or KV groups. Small quantities of viral RNA were detected by PCR in lung tissue from two pigs in the NV group (mean, 3.06 copies/g). Viral RNA was detected in lung specimens from five ferrets in the LAIV group (mean, 48.8 copies/g), two ferrets in the KV group (mean, 5.74 copies/gram), and two ferrets in the NV group (mean, 21.0 copies/gram) at

---

**FIG 3** Mean ($n=6$) ferret nasal wash influenza A virus (IAV) titers are shown by swine group exposure: live-attenuated influenza virus (LAIV), killed influenza virus (KV), or sham vaccine (NV). $N = 6$ ferrets per group. Titers at or below the assay limit of detection (LOD; 1.5 log TCID$_{50}$/ml) were assigned a nominal value of 0.0 for mean calculations. Individual ferret nasal titer data are shown separately in the supplemental material (Fig. S3). Spikes indicate standard errors of the means (SEM). The lower x axis indicates individual study days, and values are skewed ($±0.1$) to allow comparison of overlapping error bars. The upper x axis denotes timeline points of interest. Fomite transfer occurred between pigs and near-exposed (NE) ferrets only. The corresponding table below the line plot indicates the number of animals shedding infectious virus, defined as an individual titer in excess of the assay LOD by study day.
the end of the study. No viable virus was detected from PCR-positive lung tissue homogenates from either species.

DISCUSSION

Our findings directly support the implementation of preexhibition swine vaccination to protect public health from zoonotic transmission of IAV-S. We have strong evidence that LAIV vaccination of swine delayed infection of ferrets exposed to the pigs following IAV challenge (Tables 1 and 2). However, based on the survival analysis in our study, there is no evidence for the superiority of either LAIV or KV.

Intranasal administration of a high-dose viral inoculum to all swine following vaccination simulated a worst-case scenario wherein multiple pigs are directly exposed to large amounts of infectious IAV immediately prior to prolonged contact with humans. Additionally, we selected an IAV strain that was not represented among the components of either the LAIV or KV vaccine products, which would theoretically maximize the risk of infection of swine and subsequent transmission to ferrets. LAIV and KV products both significantly decreased postchallenge nasal swab peak viral titers and shedding duration in swine (Fig. 1). In general, viral replication was similar in pigs vaccinated with either LAIV or KV. This was corroborated by air sampling data showing the highest levels of IAV in the study room housing NV swine and reduced levels in the LAIV and KV study rooms (Fig. 2). Together, decreased shedding and IAV air levels in the LAIV and KV groups indicate prior use of either vaccine would reduce risk of virus spillover to humans if swine become infected during an exhibition.

No infectious virus was recovered from LAIV or KV pig samples collected at 7, 9, and 12 dpc, but one nasal swab sample collected from a pig in the LAIV group at 11 dpc contained viable virus. This pig may have been reinfected via respiratory droplet transmission from exposed ferrets still shedding IAV immediately prior to that sampling. Alternatively, the animal may have contacted nasal secretions deposited on enclosure
surfaces prior to collection of the nasal swab. Because the typical stay of exhibition swine at shows is less than 11 days, the potential impact of this outlier is limited in the field setting.

National health authority recommendations have supported limiting the length of stay for swine at agricultural exhibitions to 72 h or less to minimize potential spread of IAV among show pigs (5, 7). While both the LAIV and KV groups experienced earlier and lower peak shedding, corresponding with overall reductions in cumulative shedding compared to NV pigs, they continued to shed virus for several days beyond 72 h postchallenge. Combining the limited length of stay approach with preexhibition vaccination of swine would further reduce risk of IAV transmission from swine to humans at agricultural exhibitions. Since LAIV and KV pigs experienced reduced cumulative shedding compared to NV pigs, use of either vaccine product would be advisable over no vaccine use in a field setting.

Given the similarities in viral shedding characteristics for the LAIV and KV swine groups, the presence of decreased shedding in ferrets exposed to LAIV pigs compared to ferrets exposed to KV pigs was unexpected (Fig. 1 and 3; see also Fig. S1 in the supplemental material). This trend was present regardless of contact type (NE or FE) between the ferrets and pigs (Fig. S1). We hypothesized postchallenge selection of viral mutants within the swine groups could have led to infection of ferrets with viruses

![FIG 5](image-url) Mean change in ferret weight from baseline (%) is shown by swine group exposure: live-attenuated influenza virus (LAIV), killed influenza virus (KV), or sham vaccine (NV). N = 6 ferrets per group. Spikes indicate standard errors of the means (SEM).

TABLE 1 Pairwise survival analysis RR with 95% CI and P values<sup>a</sup>

| Comparison       | RR    | 95% CI      | P value |
|------------------|-------|-------------|---------|
| Vaccination group|       |             |         |
| KV versus NV     | 0.88  | 0.60, 1.31  | 0.528   |
| LAIV versus NV   | 0.66  | 0.46, 0.95  | 0.028   |
| Exposure group   |       |             |         |
| FE versus NE     | 0.89  | 0.65, 1.21  | 0.437   |

<sup>a</sup>AAbbreviations: NE, near-exposed; FE, far-exposed; KV, killed influenza virus; LAIV, live-attenuated influenza virus; NV, sham vaccine.
MATERIALS AND METHODS

Use of either LAIV or KV vaccination in market-age swine was capable of decreasing viral shedding following direct intranasal challenge with a high dose of a contemporary IAV-S associated with zoonotic transmission. Ferrets exposed to LAIV-vaccinated pigs experienced delayed onset to infection, decreased clinical signs, and reduced viral shedding following direct intranasal challenge with a high dose of a contemporary IAV-S associated with zoonotic transmission. Ferrets exposed to LAIV-vaccinated pigs experienced delayed onset to infection, decreased clinical signs, and reduced viral replication, although additional investigation into the underlying mechanism of this apparent benefit is required. Vaccination of exhibition swine should reduce the risk of virus spillover to humans and may prevent emergence of IAV-S with pandemic potential.

## TABLE 2 Pairwise survival analysis OR and corresponding VE

| Vaccine | OR  | 95% CI | VE (%) |
|---------|-----|--------|--------|
| KV      | 0.61| 0.13, 2.87 | 39 (187, 87) |
| LAIV    | 0.19| 0.04, 0.84  | 81 (16, 96)  |

*aAbbreviations: KV, killed influenza virus; LAIV, live-attenuated influenza virus.
*bNumbers in parentheses are confidence limits for the vaccine efficacy on the odds ratio scale where an odds ratio of 1 corresponds to 0% efficacy and an odds ratio of 0 corresponds to 100% efficacy.

exhibiting altered replication kinetics. The observed serine A138S mutation has been associated with increased infectivity of swine nasal epithelial cell cultures, although additional mutations are required to achieve this phenotype (12). The A138S mutation occurred at different frequencies across the swine treatment groups, and identification of the mutation in ferrets exposed to NV pigs makes it less clear if vaccine use in pigs selected for or against these mutants. The potential impact of vaccine-induced selection pressure on swine-transmitted IAV warrants further investigation.

Altered infectivity of transmitted virus from LAIV swine due to increased mucosal immunity was considered to explain decreased shedding in LAIV group ferrets because LAIV vaccine should have stimulated both serum IgG and mucosal IgA production, whereas KV vaccine should only elicit serum IgG production (13). However, if mucosal immunity were impacting LAIV pig-shed virus infectivity, we would have expected a decrease in LAIV swine viral titers compared to KV swine titers, since *in vitro* viral quantification relied on successful infection of MDCK cells.

Use of either LAIV or KV vaccination in market-age swine was capable of decreasing viral shedding following direct intranasal challenge with a high dose of a contemporary IAV-S associated with zoonotic transmission. Ferrets exposed to LAIV-vaccinated pigs experienced delayed onset to infection, decreased clinical signs, and reduced viral replication, although additional investigation into the underlying mechanism of this apparent benefit is required. Vaccination of exhibition swine should reduce the risk of virus spillover to humans and may prevent emergence of IAV-S with pandemic potential.

Ohio State’s Institutional Animal Care and Use and Institutional Biosafety Committees approved protocol no. 2018A0000108 and 2018R00000067, respectively.

**Swine vaccination and challenge.** Fifteen market-age (approximately 6 months of age and weighing >100 kg), male-castrated, mixed-breed domestic pigs from a commercial swine herd known to be free of IAV were assigned to one of three vaccine treatment groups consisting of five pigs each. Swine IAV-naïve status was confirmed via serology prior to vaccination using nucleoprotein enzyme-linked immunosorbent assay (see Text S1 in the supplemental material). Vaccine treatment groups were LAIV, KV, and NV. LAIV product virus strains represent two distinct IAV-S clades, H1 gamma2 beta-like (clade 1A.2.3-like) and H3 cluster I (clade 3.1990.1) (14, 15), KV product virus strains represent four distinct IAV-S clades, H1 gamma (clade 1A.3.3.3), H1 delta1 (clade 1B.2.2), H3 cluster IV-A (clade 3.1990.4.1), and H3 cluster IV-B (clade 3.1990.4.2-3) (11). NV swine received a single intranasal vaccination with sterile saline (1.0 ml) and served as the experimental control group. Single-dose (LAIV and NV) and multiple-dose (KV) vaccination regimens were administered according to the manufacturer’s instructions and timed so pigs were fully vaccinated before IAV challenge (Fig. 6A).

Swine were group-housed in a raised-deck enclosure in a modified biosafety level 2 (BSL-2) facility under constant negative air pressure (Text S1) with an estimated 42 room air changes per hour (study room volume [gross], 81.191 m³). One day prior to challenge, swine were confirmed to be IAV negative by nasal swab quantitative reverse transcription-PCR screen and received a single intramuscular injection of 1.0 ml/20 kg of body weight cefiotur crystalline free acid. Viral challenge was performed at 25 days postvaccination (study day 0). For virus challenge, pigs each received a single, 1.0-ml, intranasal dose (1 × 10^5 50% tissue culture infectious dose [TCID50]/ml) of A/swine/Ohio/16TOSU4788/2016(H3N2), which is a human-like H3 IAV-S (clade 3.2010.1). This virus shares 90% HA segment amino acid identity with component strains in both the LAIV and KV vaccines. The percent HA amino acid differences between H3-subtype vaccine component strains and A/swine/Ohio/16TOSU4788/2016(H3N2) were determined by pairwise alignment of the protein sequences using the MUSCLE alignment program in the Geneious Prime 2021.0.3 software platform: 10.6% for H3 cluster I (clade 3.1990.1) in the LAIV, 12.7% for H3 cluster IV-A (clade 3.1990.4.1), and 12.7% for H3 cluster IV-B (clade 3.1990.4.2-3) in the KV (16). The A/swine/Ohio/16TOSU4788/2016(H3N2) challenge virus was isolated from swine in 2016 and is the same virus as A/Ohio/27/2016(H3N2v), a variant IAV isolated from a human following zoonotic
transmission; the latter virus was previously shown to successfully infect naive ferrets and induce mild to moderate clinical disease (17).

**Ferret exposure to swine.** Eighteen male domestic ferrets 4 to 5 months of age were used in this study. Ferrets were confirmed influenza naive by hemagglutination inhibition assay before exposure to challenged swine. Groups of six ferrets were randomly assigned to one of the three swine groups (LAIV, KV, or NV) and introduced to the study room 1 day following swine challenge. Ferrets were individually housed in stainless steel wire cages with either near exposure or far exposure to pigs in the study room. Ferret cages were separated by acrylic barriers to minimize ferret-to-ferret aerosol transmission. Far-exposed (FE; n = 3 ferrets) cages were placed with the front of the cage 45 cm from the swine enclosure. Near-exposed (NE; n = 3 ferrets) cages were placed with the front of the cage 5 cm from the swine enclosure.

---

**FIG 6** (A) Timing of vaccine treatments for LAIV (live-attenuated influenza virus), KV (killed virus), or NV (sham) swine groups leading up to intranasal challenge with H3N2 subtype IAV (H3 human-like; 3.2010.1). (B) Timeline of animal (pig, near-exposed [NE] ferret, far-exposed [FE] ferret) nasal sample collection, study room air sample collection, and pig-ferret contact occurring for each swine group (LAIV, KV, and NV).
enclosure. All ferrets had access to fabric hammocks for the entire study; however, the NE ferrets had their original hammocks replaced on study day two with hammocks that had been in contact with the pigs to simulate physical contact between NE ferrets and pigs. To accomplish this, hammocks were placed inside Jingle Ball enrichment devices within the swine enclosure for 4 h, during which time the swine played with the devices and deposited nasal secretions on the hammocks. After 4 h, hammocks were removed and placed into the cages of NE ferrets for the duration of the study period.

Sample collection and animal observation. Swine nasal swabs, ferret nasal washes, and study room air samples were collected on study days −1 (just swine nasal swab), 1, 3, 5, 7, 9, and 11 and stored at −80°C in sterile brain heart infusion broth; an additional nasal wash sample was collected from ferrets on day 12 (Fig. 6B). Nasal samples from individual pigs were collected using sterile polyester-tipped swabs. Ferret nasal wash samples were collected under sedation. Air samples at each time point were collected over three 15-min intervals using NIOSH air sampling devices placed behind FE ferret cages and connected to a continuous air pump unit (18).

Swine were observed daily to detect the presence of lethargy, nasal discharge, coughing, elevated respiratory rate (>40 breaths per minute), or weight loss, indicated by decreased body condition score. Lethargy and nasal signs in ferrets were assessed using an established scoring system (19). Ferret weights were recorded daily, and rectal temperatures were recorded during nasal wash collection. Animals were humanely euthanized by barbiturate overdose on study day 12, and postmortem tissue collection was performed immediately thereafter.

Sample processing and analysis. Swine, ferret, and air samples were processed for IAV detection using quantitative reverse transcription-PCR as previously described (20, 21). To generate an overall concentration of IAV genome copy number per liter of air, quantification data were summed from stage 1, stage 2, and filter-stage air sampling device runs. Virus in PCR-positive samples was quantified by endpoint dilution assay in MDCK cell culture, and final viral titers were determined using the method of Reed and Muench (22). Shedding of infectious virus was indicated by TCID\textsubscript{50} titers exceeding the assay limit of detection (LOD; 1.5 log TCID\textsubscript{50}/ml). Quantitative nasal and air sample data were log transformed for area under the curve (AUC) analysis. Samples below the LOD were assigned a nominal value of 0.0 log TCID\textsubscript{50}/ml for calculation of mean viral titers and AUC analysis. Descriptive statistics and intergroup comparisons using the two-sample Mann-Whitney test (two sided) was performed with STATA (software version 14.2). A significance threshold of a P value of <0.05 was used for hypothesis testing.

Formalin-fixed tissues were routinely processed and stained with hematoxylin and eosin. A modified semiquantitative scoring approach was devised to assess upper and lower respiratory tract histopathology (23–25) (Text S1).

Pairwise survival analysis. Infection and the onset of infectiousness were both defined to be a TCID\textsubscript{50}/ml greater than zero. In each vaccine group, all ferrets were assumed to be at risk of infection from all swine. Ferret-to-ferret pairs were excluded. Each swine-ferret pair was assumed to be at risk of transmission while the pig was exhibiting clinical signs and shedding virus and the ferret was not infected. These pairs were assigned an event indicator equal to one. In each pair, the swine vaccination group (LAIV, KV, or NV) and contact type (NE or FE) were covariates. The reference groups were NV and NE, respectively.

In this data set, there are only two distinct failure times (2 days and 4 days), so we used a parametric regression model (26). We fit the model using exponential, Weibull, and log-logistic failure time distributions and compared them using the Akaike information criterion (AIC). Our results are based on the log-logistic model (AIC, 53.8). We used likelihood ratio confidence intervals for the model coefficients; these are slightly more accurate than Wald confidence intervals in small samples. The log-logistic failure time distribution implies a constant odds ratio (OR) for the probability of infection within any given time interval. With a shape parameter of γ, the rate ratio (RR) is r = OR = r\textsuperscript{γ}. Because \( r = \frac{d}{d} \) depends on multiple parameters, we used the delta method on the log scale to calculate a 95% confidence interval.

Whole-genome viral sequencing. IAVs recovered from ferret nasal washes were sequenced to validate that there were no external introductions of non-challenge strain IAV. Reverse transcription and targeted IAV genome amplification were performed with IAV-specific primers (Text S1). The amplicons were purified, followed by quantification of DNA. The DNA library was prepared according to the manufacturer’s protocol and run on the MiSeq platform. Sequences were assembled using IRMA (27). Nucleotide and amino acid sequences were then aligned and visualized using MEGA (28).

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.

TEXT S1, DOCX file, 0.02 MB.

FIG S1, TIF file, 2.7 MB.

FIG S2, TIF file, 2.7 MB.

FIG S3, TIF file, 2.8 MB.

TABLE S1, DOCX file, 0.02 MB.

TABLE S2, DOCX file, 0.02 MB.

ACKNOWLEDGMENTS
We thank the CPMPSR at Ohio State for tissue specimen processing and Kara Corps for their guidance during histologic evaluation of tissue specimens. We also extend our
gratitude for assistance provided by University Laboratory Animal Resource animal husbandry and veterinary staff at Ohio State. We thank William G. Lindsay (CDC/NIOSH) for providing NIOSH air samplers. Scientific editing was provided by Rhymes with Orange, LLC.

Funding for this project was provided by Boehringer Ingelheim Vetmedica, Inc. While C.G. and other BIVI employees participated in the overall study design and manuscript preparation, the collection and analysis of experimental data were performed independently by J.N.L., E.K., S.W.N., S.E.L., J.M.N., D.S.M., and A.S.B. to limit the potential for commercial bias.

REFERENCES
1. CDC. 2011. Swine-origin influenza A (H3N2) virus infection in two children—Indiana and Pennsylvania, July-August 2011. MMWR Morb Mortal Wkly Rep 60:1213–1215.
2. CDC. 2012. Update: influenza A (H3N2) transmission and guidelines—five states, 2011. MMWR Morb Mortal Wkly Rep 60:1741–1744.
3. Bliss N, Nelson SW, Nolting JM, Bowman AS. 2016. Prevalence of influenza A virus in exhibition swine during arrival at agricultural fairs. Zoonoses Public Health 63:477–485. https://doi.org/10.10111/zzp.12252.
4. Bowman AS, Walia RR, Nolting JM, Vincent AL, Kilian ML, Zenkovich MM, Lorbach JN, Lautebach SE, Anderson TK, Davis CT, Zanders N, Jones J, Jang Y, Lynch B, Rodriguez MR, Blanton L, Lindstrom SE, Wentworth DE, Schiltz J, Averill JJ, Forshey T. 2017. Influenza A(H3N2) virus in swine at agricultural fairs and transmission to humans, Michigan and Ohio, USA, 2016. Emerg Infect Dis 23:1551–1555. https://doi.org/10.3201/eid2309.170847.
5. NASAHO, NASPHV. 2018. Measures to minimize influenza transmission at swine exhibitions. Indiana Board of Animal Health, Indianapolis, Indiana. https://www.in.gov/boah/2569.htm.
6. Bowman AS, Nolting JM, Nelson SW, Slemons RD. 2012. Subclinical influenza virus A infections in pigs exhibited at agricultural fairs, Ohio, USA, 2009–2011. Emerg Infect Dis 18:1945–1950. https://doi.org/10.3201/eid1812.121116.
7. Bowman AS, Nolting JM, Trock SC, Gregg J, Zenkovich MM, Nelson SW, et al. 2016. Limiting influenza A virus spread in pigs at agricultural fairs to protect public health. Absbr Options Control Influenza IX Final Program, absbr O-100.
8. CDC. 2014. What people who raise pigs need to know about influenza (flu). Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/flu/swineflu/people-raise-pigs-flu.htm.
9. CDC. 2018. People at high risk for flu complications. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/flu/highrisk/index.htm. Accessed 14 January 2020.
10. USDA. 2018 Summary of studies supporting USDA product licensure: Ingelvac Provenza. USDA, Washington, DC.
11. Zoetis. 2016. FluSure XP vaccine with strain update now available from Zoetis. Addition of two new H3N2 virus clusters helps offer the most relevant protection against influenza in swine. www.zoetisus.com.
12. Busch MG, Bateman AC, Landolt GA, Karasin AI, Brockman-Schneider RA, Gern JE, Suresh M, Olsen CW. 2008. Identification of amino acids in the HA of H3 influenza viruses that determine infectivity levels in primary swine respiratory epithelial cells. Virus Res 133:269–279. https://doi.org/10.1016/j.virusres.2008.01.014.
13. Boyaka PN. 2017. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J Immunol 199:99–16. https://doi.org/10.4049/jimmunol.1601775.
14. Kaiser TJ, Smiley RA, Fergen B, Eichmeyer M, Genzow M. 2019. Influenza A virus shedding reduction observed at 12 weeks post-vaccination when newborn pigs are administered live-attenuated influenza virus vaccine. Influenza Other Respir Viruses 13:274–278. https://doi.org/10.1111/irv.12630.
15. Vincent AL, Ma W, Lager KM, Janke BH, Webby RJ, Garcia-Sastre A, Richt JA. 2007. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 25:7999–8009. https://doi.org/10.1016/j.vaccine.2007.09.019.
16. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32:1792–1797. https://doi.org/10.1093/nar/gkh340.
17. Sun X, Pultz-Pensaloza JA, Belser JA, Pappas C, Pearce MB, Brock N, Zeng H, Croucher HM, Zanders N, Jang Y, Tumpey TM, Davis CT, Maines TR. 2018. Pathogenesis and transmission of genetically diverse swine-origin H3N2 variant influenza A viruses from multiple lineages isolated in the United States, 2011–2016. J Virol 92:e00665-18. https://doi.org/10.1128/JVI.00665-18.
18. Cao G, Noti JD, Blanchere FM, Lindsay WG, Beezhold DH. 2011. Development of an improved methodology to detect infectious airborne influenza virus using the NIOSH bioaerosol sampler. J Environ Monit 13:3321–3328. https://doi.org/10.1039/c1em10607d.
19. Reuman PD, Keely S, Schiff GM. 1989. Assessment of signs of influenza illness in the ferret model. J Virol Methods 24:27–34. https://doi.org/10.1016/0166-0934(89)90004-9.
20. Harmon K, Bower L, Kim WI, Pentella M, Yoon KJ. 2010. A matrix gene-based multiplex real-time RT-PCR for detection and differentiation of 2009 pandemic H1N1 and other influenza A viruses in North America. Influenza Other Respir Viruses 4:405–410. https://doi.org/10.1111/j.1750-2659.2010.00153.x.
21. Bowman AS, Nelson SW, Edwards JL, Hofer CC, Nolting JM, Davis IC, Slemons RD. 2013. Comparative effectiveness of isolation techniques for contemporary influenza A virus strains circulating in exhibition swine. J Vet Diagn Invest 25:82–90. https://doi.org/10.1177/1040638712470449.
22. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493–497.
23. Detmer SE, Gramer MR, King VL, Mathur S, Rapp-Gabrielsson VJ. In vivo evaluation of vaccine efficacy against challenge with a contemporary field isolate from the alpha cluster of H1N1 swine influenza virus. Can J Vet Res 77:24–32.
24. Smith JH, Nagy T, Driskell E, Brooks P, Tompkins SM, Tripp RA. 2011. Comparative pathology in ferrets infected with H1N1 influenza A viruses isolated from different hosts. J Virol 85:7572–7581. https://doi.org/10.1128/JVI.00512-11.
25. Kuiken T, van den Brand J, van Riel D, Pantin-Jackwood M, Swayne DE. 2010. Comparative pathology of select agent influenza A virus infections. Vet Pathol 47:893–914. https://doi.org/10.1177/0300985810378651.
26. Kenah E. 2019. Painful survival analysis of infectious disease transmission data, p 221–244. In Held L, Hens N, O’Neill P, Wallinga J (ed). Handbook of infectious disease data analysis, 1st ed. Taylor & Francis Group, LLC, Boca Raton, FL.
27. Shepard SS, Meno S, Bahl J, Wilson MM, Barnes J, Neuhaus E. 2016. Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler. BMC Genom 17:708. https://doi.org/10.1186/s12864-016-3030-6.
28. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. 2018. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 35:1547–1549. https://doi.org/10.1093/molbev/msy096.